- Home
- DHY vs TLSA Comparison
DHY vs TLSA Comparison
Compare DHY & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.67
Company Overview
Basic Information| Metric | DHY | TLSA |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.2M | 182.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | DHY | TLSA |
|---|---|---|
| Price | $2.02 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 569.1K | 306.1K |
| Earning Date | 01-01-0001 | 05-06-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.77 | $0.63 |
| 52 Week High | $2.08 | $2.60 |
Technical Indicators
Market Signals| Indicator | DHY | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 55.53 |
| Support Level | $2.01 | $1.36 |
| Resistance Level | $2.05 | $1.58 |
| Average True Range (ATR) | 0.02 | 0.13 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 20.20 | 81.40 |
Price Performance
Historical Comparison DHY
TLSA
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.